| Literature DB >> 32265475 |
Alice Senizza1, Gabriele Rocchetti1, Maria Luisa Callegari1,2, Luigi Lucini3, Lorenzo Morelli1.
Abstract
Despite clinical and research interest in the health implications of the conjugation of linoleic acid (LA) by bifidobacteria, the detailed metabolic pathway and physiological reasons underlying the process remain unclear. This research aimed to investigate, at the molecular level, how LA affects the metabolism of Bifidobacterium breve DSM 20213 as a model for the well-known LA conjugation phenotype of this species. The mechanisms involved and the meaning of the metabolic changes caused by LA to B. breve DSM 20213 are unclear due to the lack of comprehensive information regarding the responses of B. breve DSM 20213 under different environmental conditions. Therefore, for the first time, an untargeted metabolomics-based approach was used to depict the main changes in the metabolic profiles of B. breve DSM 20213. Both supervised and unsupervised statistical methods applied to the untargeted metabolomic data allowed confirming the metabolic changes of B. breve DSM 20213 when exposed to LA. In particular, alterations to the amino-acid, carbohydrate and fatty-acid biosynthetic pathways were observed at the stationary phase of growth curve. Among others, significant up-regulation trends were detected for aromatic (such as tyrosine and tryptophan) and sulfur amino acids (i.e., methionine and cysteine). Besides confirming the conjugation of LA, metabolomics suggested a metabolic reprogramming during the whole growth curve and an imbalance in redox status following LA exposure. Such redox stress resulted in the down-accumulation of peroxide scavengers such as low-molecular-weight thiols (glutathione- and mycothiol-related compounds) and ascorbate precursors, together with the up-accumulation of oxidized (hydroxy- and epoxy-derivatives) forms of fatty acids. Consistently, growth was reduced and the levels of the oxidative stress marker malondialdehyde were higher in LA-exposed B. breve DSM 20213 than in the control.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32265475 PMCID: PMC7138814 DOI: 10.1038/s41598-020-62897-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Growth curve of B. breve DSM 20213 cultivated for 48 h in MRS Cys either with or without addition of linoleic acid (LA). LA was added to MRS medium at the final concentration of 0.5 g/L.
Figure 2Unsupervised hierarchical cluster analysis (HCA) of the metabolite profile of B. breve DSM 20213 + linoleic acid (LA) vs B. breve DSM 20213 (similarity: ‘Euclidean’; linkage rule: ‘Ward’) following 48 h of exposure. Compound intensity was used to build up the heat map, on the basis of which the clusters were generated. This figure was generated in Mass Profiler professional version B.12.04 (Agilent technologies).
Figure 3Supervised Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA) score plot on the metabolite profile of B. breve DSM 20213 + linoleic acid (LA) vs. B. breve DSM 20213. Samples were collected at the end of lag phase, during the log phase and at the stationary phase; individual replications (n = 3) are given in the class prediction model score plot. This figure was produced in Simca 13 (Umetrics).
Biosynthetic pathways considering B. breve DSM 20213 + linoleic acid (LA) vs B. breve DSM 20213, as resulted by Pathway Tools Omics Dashboard for MetaCyc (www.metacyc.org).
| Amino acids | LogFC (average) | 4 | −7 | −1 |
| LogFC (cumulative) | 34 | −52 | −17 | |
| Fatty Acids and Lipids | LogFC (average) | 8 | −7 | 0.8 |
| LogFC (cumulative) | 291 | −259 | 31 | |
| Carbohydrates | LogFC (average) | 5 | −12 | −0.3 |
| LogFC (cumulative) | 31 | −72 | 3 | |
| Amines and polyamines | LogFC (average) | 5 | −11 | 7.3 |
| LogFC (cumulative) | 33 | −74 | 44 | |
| Cofactors | LogFC (average) | 4 | −7 | −0.4 |
| LogFC (cumulative) | 94 | −158 | −21 | |
| Nucleosides-Nucleotides | LogFC (average) | 10 | −7 | −6.2 |
| LogFC (cumulative) | 62 | −39 | −56 | |
| Secondary metabolites | LogFC (average) | 0 | −10 | 0.3 |
| LogFC (cumulative) | −40 | −1422 | 135 | |
| Cell structures | LogFC (average) | 11 | −6 | 1.2 |
| LogFC (cumulative) | 112 | −62 | 10 | |
| Metabolic regulators | LogFC (average) | 10 | −10 | −0.4 |
| LogFC (cumulative) | 50 | −48 | −3 | |
| Other biosynthesis | LogFC (average) | 7 | −7 | −1.8 |
| LogFC (cumulative) | 66 | −70 | −41 |
Each main pathway is provided together with the average Log Fold Change value (LogFC) and the cumulative LogFC value, considering lag, log and stationary (48 h) phases.
Discriminant compounds (as resulted by OPLS-DA) better discriminating the changes on primary metabolism and redox stress. Each compound is provided together with the corresponding VIP score, LogFC value (B. breve DSM 20213 + LA vs B. breve DSM 20213) and accumulation.
| VIP score (OPLS-DA) | LogFC ( | Accumulation | |
|---|---|---|---|
| L-Cystathionine | 1.10 ± 1.17 | −13.3 | Down |
| L-Homocysteine | 0.90 ± 1.19 | −0.6 | Down |
| L-Methionine | 0.83 ± 1.09 | 7.0 | Up |
| L-Cysteine | 1.45 ± 0.19 | 13.0 | Up |
| 4-hydroxyphenylpyruvate | 1.15 ± 1.13 | −13.4 | Down |
| Shikimate 3-phosphate | 1.22 ± 1.05 | −11.5 | Down |
| 1-( | 1.45 ± 0.09 | −18.6 | Down |
| L-tryptophan | 1.30 ± 0.78 | 12.4 | Up |
| L-tyrosine | 1.14 ± 0.79 | 15.0 | Up |
| Imidazole-lactate | 1.15 ± 0.87 | −14.0 | Down |
| L-histidine | 0.94 ± 1.50 | 7.7 | Up |
| 9-cis, 11-trans-octadecadienoate | 0.95 ± 1.17 | 15.9 | Up |
| Vernolic acid | 1.01 ± 1.23 | 8.3 | Up |
| 2-hydroxytricosanoate | 1.05 ± 1.36 | 1.6 | Up |
| 2-hydroxydocosanoate | 1.04 ± 1.08 | 1.3 | Up |
| 4-oxopentanoate | 0.86 ± 0.61 | 12.8 | Up |
| Auricolate | 1.12 ± 1.41 | 1.7 | Up |
| 16-hydroxy-15-methyl-palmitate | 1.21 ± 0.73 | 17.8 | Up |
| L-sorbosone | 1.15 ± 1.32 | −14.9 | Down |
| 2-phospho-L-ascorbate | 1.45 ± 1.04 | −17.6 | Down |
| Glutathione amide | 0.89 ± 0.87 | −8.2 | Down |
| Glutathione amide disulfide | 0.92 ± 0.89 | −7.1 | Down |
| Glutathione amide perthiol | 1.00 ± 1.14 | −11.8 | Down |
| Mycothiol | 1.41 ± 0.62 | −17.9 | Down |
| Mycothiol-bimane conjugate | 1.15 ± 1.10 | −13.4 | Down |
| 2-aminoprop-2-enoate | 1.44 ± 1.12 | −17.3 | Down |